MEST与BRCA1共表达增高与卵巢癌更差预后及免疫浸润相关
本研究利用TCGA和GEO转录组数据,并用免疫组化验证卵巢癌标本中MEST的表达与免疫特征,发现MEST高表达与免疫细胞浸润减少及预后不良相关,MEST与BRCA1表达呈正相关,MEST高BRCA1高组在多个队列中总生存期和无进展生存期更差,PD-L1表达在MEST低BRCA1低组中预测不良生存。
要点
- MEST高表达与卵巢癌免疫细胞浸润减少及预后不良相关。
- MEST与BRCA1表达呈正相关,MEST高BRCA1高组预后更差。
- MEST高BRCA1高组中CD4+、CD57+、CD68+和MPO+细胞浸润较低。
核心结论
- MEST与BRCA1共表达可能是预测卵巢癌患者预后和免疫治疗反应的理想组合。
研究设计与样本
- 利用癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)的转录组数据,并通过卵巢癌标本免疫组化验证MEST的表达和免疫特征,使用Kaplan-Meier Plotter评估预后价值。
主要发现
- MEST高表达与卵巢癌患者免疫细胞浸润减少和预后不良相关。
- MEST与BRCA1表达呈正相关。
- MEST高BRCA1高组与CD4+细胞、CD57+细胞、CD68+细胞和MPO+细胞浸润较低相关。
- MEST高BRCA1高组在TCGA队列中总生存期更差(HR=1.57,p=0.0004),在GSE27651队列中总生存期更差(HR=4.27,p=0.0002)。
- MEST高BRCA1高组在GSE9891队列中无进展生存期更差(HR=1.76,p=0.0098),在GSE15622队列中无进展生存期更差(HR=4.80,p=0.0121)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The crosstalk between tumor microenvironment (TME) and cancer cells plays a critical role in the occurrence and development of ovarian cancer. Imprinted gene MEST is a tumor-promoting factor that modulates several carcinogenic signaling pathways. This study aimed to investigate the expression pattern of MEST and its association with immune cell infiltration. METHODS: The transcriptome data of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database was utilized, and the expression and immune characteristics of MEST were verified by immunohistochemistry of ovarian cancer specimens. Kaplan-Meier Plotter was used to assess the prognostic value in patients with ovarian cancer. RESULTS: We found that high expression of MEST was associated with diminished immune cell infiltration and worse prognosis of ovarian cancer patients in independent cohorts. There was a positive correlation between MEST and BRCA1 expression. The MESThighBRCA1high ovarian cancer group was correlated with lower infiltration of CD4+ cells, CD57+ cells, CD68+ cells and MPO+ cells, had worse overall survival (OS) in TCGA (HR = 1.57, p = 0.0004) and GSE27651 (HR = 4.27, p = 0.0002) cohorts, and predicted poor progress free survival (PFS) in GSE9891 (HR = 1.76, p = 0.0098) and GSE15622 (HR = 4.80, p = 0.0121) cohorts. Moreover, the expression of PD-L1 predicted unfavorable OS (HR = 2.48, p = 0.0415) and PFS (HR = 2.36, p = 0.0215) in MESTlowBRCA1low ovarian cancer group in GSE9891 cohort. CONCLUSION: These findings suggest that the co-expression of MEST and BRCA1 may be an ideal combination for predicting the prognosis and response to immunotherapy in patients with ovarian cancer.
引用
- Zhang J, Yu S, Li Q, et al. Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer. Gynecol Oncol. 2022. PMID: 35042621. doi:10.1016/j.ygyno.2022.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。